ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
2.205
+0.105 (5.00%)
At close: Dec 19, 2025, 4:00 PM EST
2.210
+0.005 (0.23%)
After-hours: Dec 19, 2025, 4:10 PM EST
ProQR Therapeutics Revenue
ProQR Therapeutics had revenue of 2.88M EUR in the quarter ending September 30, 2025, a decrease of -25.01%. This brings the company's revenue in the last twelve months to 15.53M, down -13.18% year-over-year. In the year 2024, ProQR Therapeutics had annual revenue of 18.91M with 190.22% growth.
Revenue (ttm)
15.53M EUR
Revenue Growth
-13.18%
P/S Ratio
12.17
Revenue / Employee
93,468 EUR
Employees
166
Market Cap
232.81M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18.91M | 12.39M | 190.22% |
| Dec 31, 2023 | 6.51M | 2.92M | 81.25% |
| Dec 31, 2022 | 3.59M | 2.26M | 169.21% |
| Dec 31, 2021 | 1.34M | -8.12M | -85.88% |
| Dec 31, 2020 | 9.45M | 7.52M | 388.98% |
| Dec 31, 2019 | 1.93M | -3.83M | -66.45% |
| Dec 31, 2018 | 5.76M | 4.27M | 285.35% |
| Dec 31, 2017 | 1.50M | -333.00K | -18.22% |
| Dec 31, 2016 | 1.83M | -1.41M | -43.49% |
| Dec 31, 2015 | 3.24M | 2.92M | 933.55% |
| Dec 31, 2014 | 313.00K | 197.00K | 169.83% |
| Dec 31, 2013 | 116.00K | 93.00K | 404.35% |
| Dec 31, 2012 | 23.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PRQR News
- 19 days ago - ProQR to Participate in 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 6 weeks ago - ProQR Announces Third Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 6 weeks ago - ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript - Seeking Alpha
- 2 months ago - ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025 - GlobeNewsWire
- 2 months ago - ProQR to Participate in Upcoming Investor Conferences in October 2025 - GlobeNewsWire
- 4 months ago - ProQR Announces Second Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 5 months ago - ProQR Announces Upcoming Presentation at RNA Editing Summit - GlobeNewsWire
- 6 months ago - ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP - GlobeNewsWire